Trust Bloomberg Tax's Premier International Tax offering for the news and guidance to navigate the complex tax treaty networks and business regulations.
By Joe Kirwin
The German pharmaceutical industry hailed a European court opinion stating German tax authorities must allow drugmakers to calculate value-added tax on sales to private health insurance companies as they would for public health insurance funds.
In a case ( C-462/16) that could have a major VAT impact on drug sales in Germany and other EU member states, European Court of Justice Advocate General Evgeni Tanchev July 11 backed a challenge by German drugmaker Boehringer Ingelheim Pharma GmbH, which was denied the right to take into consideration discounts when calculating VAT prices to private health insurance funds.
The legal dispute stems from a position taken by German tax authorities, who insisted that because individuals are reimbursed for discounts on sales to private insurance funds, they are not—legally speaking—the final consumers. Upon an appeal by Boehringer, the German tax court asked the ECJ to rule, based on EU VAT law, on the different treatment when it comes to determining VAT turnover taxes “considering public health insurance funds are ultimate consumers in the chain of supply of Boehringer’s pharmaceutical products and private health insurers are not.”
Indicative of the importance of the case, the U.K. intervened on behalf of German tax authorities. Both the German and U.K. governments argued that a previous ECJ ruling (C-317/94) supports their argument that if discounts are to be taken into consideration when calculating VAT, the consumer must be part of the transaction chain.
Klaus Herkenroth, a German-based attorney with Jones Day, told Bloomberg BNA July 12 that on one hand, it seems obvious the position of pharmaceutical companies vis-a vis private insurance companies is no different from those of public health insurance companies, but on the other hand, “VAT is of a very formalistic nature and in that respect, the position of public and private health insurance companies is different.
“Nevertheless, in my view it should be controlling that the VAT base is formed by the consideration obtained, and here the consideration obtained by pharmaceutical companies is equally reduced in both cases,” Herkenroth said.
The final judgment of the ECJ is due later in 2017. In the majority of ECJ cases, the EU high court supports the position of the AG.
To contact the reporter on this story: Joe Kirwin in Brussels at email@example.com
To contact the editor responsible for this story: Penny Sukhraj at firstname.lastname@example.org
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)